|Bid||31.64 x 300|
|Day's Range||48.00 - 50.74|
|52 Week Range||37.35 - 55.38|
|PE Ratio (TTM)||-21.20|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Neurocrine may have left the door open for Teva to get an early lead in Tourette's syndrome, an analyst said Wednesday.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) shares fell sharply Wednesday following a disappointing phase 2 study of Ingrezza (valbenazine), a pediatric Tourette's syndrome drug . The company announced ...